BMJ23d
Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study
Objectives This work aimed to resolve the conflicting reports on Prevotellaceae abundance in the development of rheumatoid arthritis (RA) and to observe structural, functional and temporal changes in ...
BMJ17h
Bilateral parotid gland involvement in Wegener granulomatosis
Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK Dr A Saha, Department of Rheumatology, Third Floor, Lambeth Wing, St Thomas’ Hospital, Westminster Bridge Road, ...
BMJ13d
Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk
Objective We aimed to identify specific genetic-respiratory disease endotypes for rheumatoid arthritis (RA) risk. Methods This case–control study used the Mass General Brigham (MGB) and Mayo Clinic ...
BMJ1d
POS0107 IDENTIFICATION OF POTENTIAL GENES AND TREATMENT RESPONSE TO TOFACITINIB THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS
3 Institute for Medical Research, National Institutes of Health Complex, Allergy and Immunology Research Center, Selangor Darul Ehsan, Malaysia 4 Hospital Selayang, Department of Medicine, Selangor ...
BMJ2d
Association of circulating CXCL10 and CXCL11 with systemic sclerosis
Correspondence to Professor Clara Crescioli, Department of Movement, Human and Health Sciences, Section of Health Sciences, Università degli Studi di Roma “Foro Italico”, Rome 00135, Italy; ...
BMJ6d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ11d
AB0379 BARICITINIB IN POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS: REPORT OF SIX CASES
Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).
BMJ4d
Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs
Correspondence to Dr Jörg H W Distler, Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, ...
BMJ2d
Not only synovitis but also tenosynovitis needs to be considered: why it is time to update textbook images of rheumatoid arthritis
Correspondence to Professor Annette van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands; A.H.M.van_der_Helm{at}lumc.nl Rheumatoid arthritis (RA) is ...
BMJ6d
Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2
Correspondence to Professor Daozhang Cai and Dr Xiaochun Bai, Department of Orthopedics, Academy of Orthopedics - Guangdong Province, Orthopedic Hospital of Guangdong Province, The Third Affiliated ...
BMJ12d
LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
11 University of Pennsylvania, Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, PA, United States of America 12 University of Pennsylvania, Division ...
BMJ5d
Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study
Objective To investigate the rate of serious bacterial, viral or opportunistic infection in patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis factor inhibitors ...